Quest Diagnostics shares fell 5.1% after CMS disclosed that Medicare had been paying about 16% more for laboratory services than private insurers. CMS plans to reduce laboratory reimbursement rates by up to 15% starting January 1, 2027, aiming to save taxpayers approximately $1 billion annually.
Government healthcare programs account for a portion of Quest’s revenue. According to the company’s 2025 10-K filing, about 11% of Quest’s revenue came from CMS reimbursements. A full 15% rate reduction could result in roughly a 1.65% decline in Quest’s total annual revenue. Quest has highlighted Medicare and Medicaid reimbursement cuts as a potential business risk, noting such changes may affect testing volumes, revenue, and administrative costs.
The article notes the possibility of successive 15% reimbursement cuts from 2027 through 2029. If all occur as projected, the cumulative impact could reduce nearly 5% of Quest’s overall business under a worst-case scenario. This adds pressure amid ongoing competition and evolving healthcare market conditions in the diagnostic testing industry.
Despite this, Quest’s 5.1% share-price decline after the announcement exceeds the estimated worst-case revenue impact. The author suggests investors may have already priced a substantial portion of the reimbursement risk into the stock. Moving forward, Quest’s ability to manage costs, maintain testing volumes, and advance growth and efficiency initiatives will be critical as reimbursement changes take effect.
